Mesothelioma and the Promising New Hippo Biomarker

Mesothelioma and the Promising New Hippo Biomarker

A new review in Targeted Oncology looks at a promising new Hippo biomarker in malignant pleural mesothelioma. The new biomarker is rooted in the mesothelioma molecular pathway. A molecular pathway is how molecules work together inside your body. These pathways control cell function. And they are important in developing mesothelioma treatments. Think of molecular pathways as the airport tower controller. These pathways tell mesothelioma treatments where to go and what to do in the body. If doctors can understand how pathways work, they can develop better treatments. The goal is to develop more, and more effective, mesothelioma treatments. Promising Hippo Pathway in Malignant Pleural Mesothelioma While several drugs have been approved for treating mesothelioma, there aren’t a lot. This is … Continue reading Mesothelioma and the Promising New Hippo Biomarker »

Serum IgG4: A New Biomarker for Mesothelioma Pleural Effusion

Serum IgG4: A New Biomarker for Mesothelioma Pleural Effusion

Egyptian scientists say a new biomarker is very good at identifying mesothelioma. Pleural effusions are pockets of excess fluid. They collect around the lungs of people with certain kinds of cancer and other conditions. Biomarkers in pleural effusions are proteins and other substances found in mesothelioma patients. The new study suggests that using this biomarker the right way can lead to more accurate diagnoses. The Importance of Biomarkers in Pleural Effusions Pleural mesothelioma is a rare cancer of the lung lining. It is a challenge to diagnose. The early symptoms can be as vague as cough and fatigue. But an accurate diagnosis is often the difference between life and death. As tumors grow, mesothelioma patients produce pleural effusions or ‘water … Continue reading Serum IgG4: A New Biomarker for Mesothelioma Pleural Effusion »

Identifying New MicroRNA Tumor Biomarkers for Mesothelioma

Identifying New MicroRNA Tumor Biomarker for Mesothelioma

Identifying New MicroRNA Tumor Biomarkers for Mesothelioma Italian researchers have taken an important step forwards in what amounts to a microRNA tumor biomarker for mesothelioma. Exposure to asbestos fibers causes malignant pleural mesothelioma. An early diagnosis and comprehensive health monitoring is vital for patients exposed to asbestos fibers. Researchers at the University of Catania in Italy say these two clinical issues “may be solved by the identification of specific biomarkers.” A new article in Nature Scientific Reports identifies RNA molecules could serve as a microRNA signature for mesothelioma. This “signature” could help doctors distinguish mesothelioma from other types of cancer. The Challenge of Mesothelioma Diagnosis Pleural mesothelioma is particularly hard to diagnose. The early symptoms of mesothelioma are similar to the … Continue reading Identifying New MicroRNA Tumor Biomarkers for Mesothelioma »

Genomic Experts Report Most Complete Picture of Mesothelioma to Date

Genomic Experts Report Most Complete Picture of Mesothelioma to Date

Australian and American genomic experts have completed a key step in improving the treatment of pleural mesothelioma. A new study gives results from a large study of malignant pleural mesothelioma Pleural mesothelioma is a type of cancer that develops on the thin layer of tissue that covers the lungs and chest wall. Asbestos causes mesothelioma and other asbestos-related diseases. Asbestos was used in thousands of industrial, commercial, construction, automotive, and consumer products. Pleural mesothelioma occurs in about 2,000 people in the United States every year. Scientists at the National Centre for Asbestos-Related Disease have taken a dramatic leap forward in the understanding of pleural mesothelioma. DNA Genes Impact Personalized Treatment Plans Previous genomic studies of malignant pleural mesothelioma were limited. … Continue reading Genomic Experts Report Most Complete Picture of Mesothelioma to Date »

New Tips for Diagnosing Malignant Peritoneal Mesothelioma

New Tips for Diagnosing Malignant Peritoneal Mesothelioma

Malignant peritoneal mesothelioma is an aggressive cancer that often mimics other conditions. This can make it difficult to get a definitive diagnosis. But a new report in Pathology Case Reviews provides tips for identifying peritoneal mesothelioma. Diagnosing Malignant Peritoneal Mesothelioma Mesothelioma is usually diagnosed after a person experiencing symptoms goes to a doctor. Patients often complain of vague abdominal symptoms, such as pain, nausea, bloating, weight loss. Distinguishing peritoneal mesothelioma from other cancers is important to ensure appropriate treatment. One thing a doctor may do is perform a tissue biopsy. The doctor will remove a part of the tissue (suspected mesothelioma) for examination. A biopsy is the “gold standard” and the single most important procedure for an accurate diagnosis. Doctors … Continue reading New Tips for Diagnosing Malignant Peritoneal Mesothelioma »

New Advancements in Personalized Medicine for Mesothelioma

New Advancements in Personalized Medicine for Mesothelioma

Genomics is a new branch of medicine that involves using a patient’s genetic information to create personalized treatment. New research has begun looking at genetic personalized medicine for mesothelioma. Students from the University of Montana are developing personalized medicine for mesothelioma. Personalized Medicine and Mesothelioma Treatment Mesothelioma is a rare rare and aggressive cancer often caused by asbestos exposure. Environmental exposure to asbestos often causes a higher incidence of malignant mesothelioma. There are approximately 2,000 cases of mesothelioma diagnosed in the U.S. every year. Current standard of care involves a multi-targeted drug combination of Pemetrexid and Cisplatin. This is the only FDA approved chemotherapy for mesothelioma. Chemotherapy is a group of toxic drugs that kill mesothelioma cells by damaging their … Continue reading New Advancements in Personalized Medicine for Mesothelioma »

New Anti-Mesothelioma Antibody and Biomarker Discovered

New Anti-Mesothelioma Antibody and Biomarker Discovered

Dr. Tsuji is working on discovering specific cancer antigens for malignant mesothelioma. A new study from the Gunma University of Health and Welfare shows a new anti-mesothelioma antibody for the diagnosis and treatment of mesothelioma. The use of antibody drugs is becoming more popular in the treatment of mesothelioma. Antibody drugs are immunotherapy treatments. They recruit your body’s germ-fighting immune system to fight against mesothelioma. One the of biggest problems with mesothelioma immunotherapy is a lack of biomarkers. Mesothelioma is Difficult to Diagnose and Treat with Biomarkers Mesothelioma is a rare and aggressive cancer often caused by asbestos exposure. Malignant mesothelioma is characterized by poor prognosis and short survival. Malignant mesothelioma is considered a treatment-resistant (intractable) cancer. Clinicians and researchers … Continue reading New Anti-Mesothelioma Antibody and Biomarker Discovered »

Hope for Mesothelioma Patients with Genetic Predisposition (Germline PVs) for Cancer

Mesothelioma Patients with Genetic Predisposition for Cancer are Candidates for Personalized Medicine

Malignant pleural mesothelioma is a tumor caused by asbestos exposure. Recently, the United States Food and Drug Administration approved immunotherapy treatment for mesothelioma. But the efficacy of available treatments is still limited. Researchers are still evaluating these new therapeutic approaches. They are also working to identify subgroups of patients who could benefit from precision medicine. Precision medicine uses information about a person’s tumor to find out how well a treatment is working. One of these groups could be represented by patients with an inherited cancer syndrome. These are caused by germline pathogenic variants (PVs) in DNA repair genes. A germline pathogenic variant is a gene variant (or mutation) that is passed from parent to child. These germline PVs are hereditary. … Continue reading Hope for Mesothelioma Patients with Genetic Predisposition (Germline PVs) for Cancer »

MicroRNAs in Cancer Development and Mesothelioma Personalized Medicine

MicroRNAs in Cancer Development and Mesothelioma Personalized Medicine

A special issue was published in the Journal of Personalized Medicine. Dr. Alessandra Pulliero from the University of Genoa in Italy talks about microRNA. Specifically, the role of microRNA in cancer development and personalized medicine. A microRNA (miRNA) is a small part of an RNA molecule. MiRNAs play a key role in the regulation of gene expression in cells, including mesothelioma cells. Mesothelioma is a rare and aggressive cancer often caused by asbestos exposure. Asbestos also causes a progressive lung disease called asbestosis. Environmental exposure to asbestos often causes a higher incidence of malignant mesothelioma. Malignant mesothelioma is characterized by poor prognosis and short survival. Personalized Medicine and Mesothelioma Scientists now know that the role of miRNAs changes once they … Continue reading MicroRNAs in Cancer Development and Mesothelioma Personalized Medicine »

New Drug Targeting Fibrosis may Help Mesothelioma Patients

Targeting Fibrosis in Mesothelioma has Therapeutic Benefits

Targeting fibrosis has therapeutic benefits in mesothelioma. Most drugs have limited effects in difficult-to-treat cancers such as mesothelioma. Often this is because not enough of the drug can get into the tumor to generate an anti-tumor effect. Fibrosis is a common element of mesothelioma. It causes the area around the cancer to stiffen. Fibrosis acts as a barrier, stopping drugs from getting into the cancer tumor. This limits the immune system’s ability to detect and access the tumor to kill it. A new study is looking at how a family of proteins called lysyl oxidases can help solve this problem. These proteins are associated with fibrosis in many cancers, including mesothelioma. Oncologists targeting fibrosis and this protein family may improve … Continue reading New Drug Targeting Fibrosis may Help Mesothelioma Patients »

Get your free copy of
“Surviving Mesothelioma” Today!